¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"platelet dense body"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • body
    ¸öÅë, ü, ¼Òü
  • body attitude
    žÆÀÚ¼¼
  • body cavity
    ü°­
  • body cavity irradiation
    ü°­³»Á¶»ç
  • body composition
    ¸öÁ¶¼º, ½ÅüÁ¶¼º
  • body concept
    ½Åü°³³ä
  • body contour
    ½ÅüÀ±°û
  • body contouring
    ¸öÀ±°û¼ºÇü(¼ú)
  • body dysmorphic disorder
    ½ÅüÃßÇüÀå¾Ö
  • body ego
    ½ÅüÀÚ¾Æ
  • body fat
    üÁö¹æ, ¸öÁö¹æ
  • body fluid
    ü¾×
  • body fluid compartment
    ü¾×±¸È¹
  • body image
    ½Åü»ó
  • body image agnosia
    ÀÚ¼¼ÀνĺҴÉ(Áõ), ÀÚ¼¼½ÇÀÎÁõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • body temperature
    ü¿Â
  • total body water
    ÃÑü¾×·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • body image agnosia
    (¢¡autotopagnosia) ÀÚ¼¼ÀνĺҴÉÁõ
  • foreign body appendicitis
    À̹°Ãæ¼ö¿°
  • body
    ¸öÅë, ü, ¼Òü
  • Barr body
    (¢¡sex chromatin) ¼º¿°»öÁú
  • basal body
    ±âÀú¼Òü
  • basal body temperature
    ±âÃÊü¿Â
  • body composition
    ¸öÁ¶¼º
  • body concept
    ½Åü°³³ä
  • body contour
    ÀÎüÀ±°û
  • body contouring
    ¸öÀ±°û¼ºÇü¼ú
  • body ego
    ½ÅüÀÚ¾Æ
  • body fat
    ¸öÁö¹æ, üÁö¹æ
  • body fluid
    ü¾×
  • body heat
    ü¿­
  • body image
    ½Åü»ó, ¸ö¸ð¾ç»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • platelet refractioriness
    Ç÷¼ÒÆÇ¼öÇ÷ºÒÀÀÈ­
  • platelet rich plasma
    Ç÷¼ÒÆÇdzºÎÇ÷Àå
  • platelet satellitism
    Ç÷¼ÒÆÇÀ§¼ºÇö»ó
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®(̰×î)
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • platelet transfusion
    Ç÷¼ÒÆÇ¼öÇ÷(¡­âÃúì).
  • platelet transfusion
    Ç÷¼ÒÆÇ¼öÇ÷
  • platelet,adhesion
    À¯Âø(ë¨ó·),ºÎÂø(ݾó·),Á¢Âø(ïÈó·)
  • platelet,aggregation
    ÀÀÁý(ëêó¢), ÀÀ±«(ëêÎÔ)
  • platelet-activating factor (PAF)
    Ç÷¼ÒÆÇ Ȱ¼ºÈ­ÀÎÀÚ
  • platelet-activating factor (paf)
    Ç÷¼ÒÆÇȰ¼ºÈ­ÀÎÀÚ(úìá³÷ùüÀàõûùì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet agitator
    Ç÷¼ÒÆÇÈ¥ÇÕ±â
  • platelet antibody
    Ç÷¼ÒÆÇÇ×ü(¡­ù÷ô÷).
  • platelet concentrate
    Ç÷¼ÒÆÇ³óÃà¾× (¡­ÒØõêäû).
  • platelet concentrates=PC
    ³óÃàÇ÷¼ÒÆÇ
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·(¡­Ï¡üñد).
  • platelet disorder
    Ç÷¼ÒÆÇÁúȯ
  • platelet endothelial cell adhesion molecule 1(pecam-1)
    Ç÷¼ÒÆÇ³»ÇǼ¼Æ÷ºÐÀÚ(úìá³÷ùÒ®ù«á¬øàÝÂí­)1
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ(úìá³÷ùì×í­) 4
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Nail body
    ¹ßÅé¸öÅë
    [¿¾ ¿ë¾î] Á¶Ã¼
  • Body of metatarsal bone
    ¹ßÇ㸮»À¸öÅë
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñü
  • Body of bladder
    ¹æ±¤¸öÅë
    [¿¾ ¿ë¾î] ¹æ±¤Ã¼
  • Adipose body of cheeks
    º¼Áö¹æÃ¼
    [¿¾ ¿ë¾î] ÇùÁö¹æÃ¼
  • Body of clavicle
    ºøÀå»À¸öÅë
    [¿¾ ¿ë¾î] ¼â°ñü
  • Perineal body
    »ôÈûÁÙÁß½É
    [¿¾ ¿ë¾î] ȸÀ½Ã¼
  • Body of gland
    »ù¸öÅë
    [¿¾ ¿ë¾î] ¼±Ã¼ºÎ
  • Ciliary body
    ¼¶¸ðü
    [¿¾ ¿ë¾î] ¸ð¾çü
  • Sex chromatin [Barr body]
    ¼º¿°»öÁú¼Òü
    [¿¾ ¿ë¾î] ¼º¿°»öÁú¼Òü
  • Nail body
    ¼ÕÅé¸öÅë
    [¿¾ ¿ë¾î] Á¶Ã¼
  • Body of metacarpal bones
    ¼ÕÇ㸮»À¸öÅë
    [¿¾ ¿ë¾î] Áß¼ö(Àå)°ñü
  • Pineal body [Pineal gland]
    ¼Û°úü [¼Ö¹æ¿ï»ù]
    [¿¾ ¿ë¾î] ¼Û°úü
  • PINEAL BODY [PINEAL GLAND]
    ¼Û°úü [¼Û¹æ¿ï»ù]
    [¿¾ ¿ë¾î] ¼Û°úü
  • Body of gallbladder
    ¾µ°³¸öÅë
    [¿¾ ¿ë¾î] ´ã³¶Ã¼
  • Ultimobranchial body
    ¾Æ°¡¹Ì³¡¼Òü
    [¿¾ ¿ë¾î] Á¾»õü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PM after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr...
DCS decompression sickness; dense canalicular system; diffuse cortical sclerosis; dorsal column stimulat...
DDD AV universal [pacemaker]; defined daily dose; degenerative disc disease; dehydroxydinaphthyl disulfi...
DFECT dense fibroelastic connective tissue
DIDD dense intramembranous deposit disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PDGF Anti-platelet-derived growth factor
GPS Gray platelet syndrome
HELLP Hemolysis, Elevated Liver enzymes, and Low Platelet count
HIPA Heparin-induced platelet activation
HPA Human Platelet Alloantigens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • body language
    ½Åü ¾ð¾î, ½Åü¾î
    ¾ð¾î·Î Ç¥ÇöÇÏÁö ¾Ê°í ¸öÁþÀ̳ª ÇൿÀ¸·Î ¿øÇÏ´Â ¶æÀ» Àü´ÞÇÏ´Â ÀÇ»ç¼ÒÅë¹ýÀÌ´Ù. ÀÏ¸í ¸¸±¹ °øÅë¾î¶ó°íµµ ÇÑ´Ù. ¿¹¸¦ µé¾î ¸ñÀÌ ¸¶¸£¸é ¹° ¸¶½Ã´Â Èä³»¸¦ ³»¸é µÈ´Ù.
  • body mastery
    ½Åü ¼÷´Þ
  • body of hyoid bone
    ¼³°ñ ü
  • body of mandible
    ÇÏ¾Ç °ñü
  • body of metacarpal bones
    ¼ÕÇ㸮»À ¸öÅë
  • body of pancreas
    ÃéÀå ¸öÅë, Ãéü
  • body of stomach
    À§ ¸öÅë
  • body of tongue
    Çô ¸öÅë, ¼³Ã¼
  • body part
    ¸öÅë ºÎºÐ
  • body position
    üÀ§
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • body rocking
    ½Åü ¿äµ¿
    ¾ÉÀº ÀÚ¼¼·Î ÇàÇÏ´Â À²µ¿ÀûÀÎ ÀüÈĿ.
  • body secretion
    ½Åü ¹è¼³¹°
  • body section roentgenography
    ½Åü ÀýÆí ¹æ»ç¼± ÃÔ¿µ
    µ¿ÀǾî=tomogra
  • body shaft of metacarpal bone
    Á¤¿Ü Áß¼ö°ñü
    µ¿ÀǾî=cor
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
platelet function disorders <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(31 Dec 1997)
platelet glycoprotein gpib-ix complex Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, gpib alpha, gpib beta, and gpix. Glycoprotein ib functions as a receptor for von willebrand factor and for thrombin. Congenital deficiency of the gpib-ix complex results in bernard-soulier syndrome. The platelet glycoprotein gpv associates with gpib-ix and is also absent in bernard-soulier syndrome.
(12 Dec 1998)
platelet glycoprotein gpiib-iiia complex Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. The complex is an integrin which recognises the arginine-glycine-aspartic acid (rgd) sequence present on several adhesive proteins. As such, it is a receptor for fibrinogen, von willebrand factor, fibronectin, vitronectin, and thrombospondin. A deficiency of gpiib-iiia results in glanzmann's thrombasthenia.
(12 Dec 1998)
platelet membrane glycoproteins Surface glycoproteins on platelets which have a key role in haemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.
(12 Dec 1998)
platelet storage pool deficiency A group of disorders characterised by a decrease or lack of platelet dense bodies in which the releasable pool of adenine nucleotides and 5ht are normally stored.
(12 Dec 1998)
platelet thrombosis Thrombosis due to an abnormal accumulation of platelets.
(05 Mar 2000)
platelet tissue factor <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
platelet transfusion The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
(12 Dec 1998)
low affinity platelet factor IV Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
low platelet count <haematology> An abnormally low platelet count. Normal platelet counts are 150,000-400,000 per cubic millimetre.
Those with low platelet counts may exhibit haematuria, haematemesis, easy bruising, bleeding gums, melena (blood in stools), prolonged menses or nosebleeds. Spontaneous intracranial haemorrhage can occur with platelet counts of 10-15,000 (or less).
(27 Sep 1997)
acetone body <biochemistry> Any of the three compounds created by acetyl coenzyme A (acetoacetate, hydroxybutyrate, and acetone) which are water-soluble cellular fuels normally exported by the liver.
They can build up in the blood and body tissues because of starvation, untreated diabetes mellitus, or other disorders that interfere with carbohydrate metabolism. The body rids itself of ketones mainly through urine, but it rids itself of acetone through the lungs, which gives the breath a characteristic fruity odour. If ketones build up in the body long enough, they cause serious illness and coma (see ketoacidosis.)
(09 Oct 1997)
acute inclusion body encephalitis The most common acute encephalitis, caused by HSV-1; affects persons of any age; preferentially involves the inferomedial portions of the temporal lobe and the orbital portions of the frontal lobes; pathologically, severe haemorrhagic necrosis is present along with, in the acute stages, intranuclear eosinophilic inclusion bodies in the neurons and glial cells.
Synonym: acute inclusion body encephalitis, herpes encephalitis.
(05 Mar 2000)
adrenal body See adrenal gland.
(12 Dec 1998)
alveolar body That portion of bone in either the maxilla or the mandible which surrounds and supports the teeth.
(12 Dec 1998)
amygdaloid body Almond-shaped group of basal nuclei anterior to the inferior horn of the lateral ventricle of the brain, within the temporal lobe. The amygdala is part of the limbic system.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á